<DOC>
	<DOC>NCT01144832</DOC>
	<brief_summary>Purpose: To evaluate the efficiency of Irritable Bowel Syndrome (IBS) patients treatment with the H1-receptor antagonist ebastine. Design: Double blind randomized placebo controlled trial. IBS patients receive a 12-weeks treatment with ebastine 20mg once daily or placebo (1:1 randomization). End points: End point is the effect of treatment on clinical symptoms and visceral hypersensitivity which will be evaluated with a barostat test.</brief_summary>
	<brief_title>Irritable Bowel Syndrome (IBS) Treatment With H1-receptor Antagonists</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Ebastine</mesh_term>
	<mesh_term>Histamine H1 Antagonists</mesh_term>
	<criteria>Irritable Bowel Syndrome (ROME III criteria) age 1865 years medication: antidepressants or H1receptor antagonists pregnancy, breast feeding comorbidity: severe kidney and/or liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>visceral hypersensitivity</keyword>
	<keyword>mast cells</keyword>
</DOC>